10-K/A: Petros Pharmaceuticals Files Amended 10-K to Correct Accounting Firm Consents

Petros Pharmaceuticals has filed an amendment to its annual report to correct references to registration statements in the consents of its current and former independent accounting firms.

Summary

• Petros Pharmaceuticals filed an amendment to its annual report on Form 10-K for the year ended December 31, 2023.
• The amendment was filed solely to replace the consents of Marcum LLP and EisnerAmper LLP, the company's current and former independent registered public accounting firms, respectively.
• The original consents incorrectly referenced the company's registration statements.
• This amendment includes new certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002.
• No financial statements are included in this amendment, and it does not modify or update the original Form 10-K except for the corrected consents.
• The company had 7,000,195 shares of common stock outstanding as of May 30, 2024.
• The aggregate market value of voting and non-voting common equity held by non-affiliates was $3,145,008 as of June 30, 2023.

Sentiment

Score: 5

Explanation: The document is neutral, as it primarily addresses a technical correction. The mention of 'going concern' is a negative, but the amendment itself is a routine process.

Positives

• The company is taking steps to ensure compliance with SEC regulations by correcting the accounting firm consents.
• The company is transparent in its filing by clearly stating the purpose of the amendment.

Negatives

• The need for an amendment suggests an initial error in the original filing, which could raise concerns about internal controls.

Risks

• The company's ability to continue as a going concern is mentioned in the auditor's report, indicating potential financial instability.
• The need for a corrected filing could lead to increased scrutiny from regulators and investors.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Management Comments

• Fady Boctor, Chief Commercial Officer and Principal Executive Officer, and Mitchell Arnold, Vice President of Finance and Principal Financial Officer, certified that the report does not contain any untrue statements or omissions of material facts.

Industry Context

This filing is a routine amendment to correct a technical error and does not indicate any significant changes in the company's business or market position. It is common for companies to file amendments to correct errors in their filings.

Comparison to Industry Standards

• The need for an amended filing to correct accounting firm consents is not typical for well-established companies, but it is not uncommon for smaller reporting companies.
• The mention of 'going concern' in the auditor's report is a concern and is not typical for financially stable companies. This is a common issue for companies in the early stages of development or those facing financial challenges.

Stakeholder Impact

• Shareholders may be concerned about the initial error in the original filing and the 'going concern' mention.
• Creditors may view the 'going concern' mention as a potential risk.

Key Dates

Keywords

Form 10-K/A, amendment, accounting firm consent, Marcum LLP, EisnerAmper LLP, registration statements, financial statements, Sarbanes-Oxley Act, SEC filing